FULGENT GENETICS, INC. Debt Securities, Available-for-sale
FULGENT GENETICS, INC. (FLGT) had Debt Securities, Available-for-sale of $50.94 million as of 2020-09-30, per its 10-Q filed 2020-11-09.
Discontinued › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2020-11-09
- 2020-09-30: Debt Securities, Available-for-sale $50.94M.
- 2020-06-30: Debt Securities, Available-for-sale $63.93M.
- 2020-03-31: Debt Securities, Available-for-sale $61.32M.
- 2019-12-31: Debt Securities, Available-for-sale $58.25M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2020-09-30 | $50.94M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $63.93M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $61.32M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $58.25M 10-Q · filed 2020-11-09 |
| 2019-09-30 | $23.08M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $29.52M 10-Q · filed 2019-08-12 |
| 2019-03-31 | $33.12M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $30.68M 10-K · filed 2020-03-13 |
| 2018-09-30 | $28.36M 10-Q · filed 2018-11-09 |
| 2017-12-31 | $34.88M 10-K · filed 2019-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |